source
- GSK and Ionis report functional cure in 20% of hepatitis B patients with bepirovirsen in early trialsGSK and Ionis disclosed results from two clinical studies of their RNA‑based injection, bepirovirsen, aimed at achieving a functional cure for chronic hepatitis B. In both trials about one‑fifth o…
- CVS adds Lilly’s Foundayo and Zepbound to formularies, leveling GLP-1 market with NovoCVS Caremark announced it will place Eli Lilly’s new oral GLP-1 drug Foundayo on its formulary starting June 1 and will restore the injectable Zepbound as a preferred option from Oct 1. The change…